Introduction
Gliomas are astrocyte-derived tumors of the central nervous system, among which glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and malignant were partially addressed. The purpose of our study was to examine the role of exogenous hormones used after menopause on the incidence of glioma and GBM. The use of a prospectively collected, randomized trial data set, as found in the WHI data set, may provide additional information regarding the impact of female hormones on gliomagenesis.
Understanding the impact of these hormones may have broad implications on the pathogenesis and management of gliomas.
Materials and Methods

WHI study population and subject groups
The WHI was a multi-part clinical research project that recruited 161,808 women between the ages of 50 and 79 years into three randomized clinical trials (n=68,132) and an observational study (n=93,676), which has been described previously (Stefanick et al. 2003) . Briefly, the clinical trials included one hormone therapy clinical trial (HT CT, n=27,347), and two nonhormone therapy clinical trials (non-HT CT), which included a dietary modification (DM, n=48,835) trial and calcium/vitamin D (CaD, n=36,282) trial ( Figure 1A ). Eligible subjects could enroll in one, two or all three trials and subjects not eligible for the clinical trials were invited to enter the observational study (OS). All entering subjects underwent a careful evaluation of previous hormone use including type and duration. Women with a previous history of breast or brain cancer were excluded. Subjects in the HT CT trial were randomized and received either daily 0.625mg of conjugated equine estrogen (Premarin, Wyeth, Philadelphia), estrogen plus 2.5mg medroxyprogesterone acetate (Pempro, Wyeth, Philadelphia) or placebo.
Follow up with the subjects occurred 6 weeks after enrollment and annually thereafter. All subjects enrolled in the WHI with complete data and follow-up were included in this study. Baseline HT, oral contraceptive and clinical HT treatments determined categorization in this study (Figure 1B) . The E-alone group included 1) women who were randomized to the estrogen arm of the CT, 2) reported treatment with estrogen alone (without progesterone) at WHI trial randomization in the non-HT CT, or 3) reported treatment with estrogen at time of enrollment in the OS. Similarly, the E+P group included 1) women who were randomized to the E+P arm of the CT, 2) reported treatment with estrogen and progesterone at WHI trial randomization in the non-HT CT, or 3) reported treatment with estrogen and progesterone at time of enrollment in the OS group. The duration of hormone exposure was factored as a variable.
Placebo-controlled subjects from the HT CT were categorized as E-alone or E+P non-users depending on respective groups. Non-HT CT and OS women not using HT and with a prior hysterectomy were categorized in the E-alone non-users group, while those not using HT and without prior hysterectomies were placed in the E+P non-users group to reflect patient allocation in the HT CT trial (Chlebowski and Anderson 2012).
Glioma and GBM diagnosis
Cases of glioma (ICD-M 9380/3-9451/3) and GBM (ICD-M 9380/3 and 9440/3) were analyzed. Subjects with diagnosed brain tumors presented in a hospital inpatient or outpatient setting, and their clinical treatment and diagnosis were obtained from the medical record (Supplementary table 1) . Pathological confirmation of tumor diagnoses was noted in the majority of cases; however, treatment type including surgery, chemotherapy and radiotherapy, was not assessed in the WHI trial.
Statistical analysis
Of the 161,108 women enrolled in the WHI, this analysis includes 126,237 participants reporting Caucasian race/ethnicity at baseline. Women with a previous history of breast or brain cancer were excluded because a large percentage would be placed on anti-estrogen therapies.
Participants reporting non-Caucasian race were excluded in the final analysis because of the small number of glioma cases among them (n=11), which might have skewed the hazards modeling; however, inclusion of these subjects did not alter the final results. Subject demographic, reproductive and hormonal exposure characteristics were noted. Follow-up time began at WHI CT randomization or OS enrollment to the most recent follow-up time. Overall, 76.9% of eligible participants consented to the first extension study on March 31, 2005, the original date of WHI completion, and 75% of participants who continued consented to the 2010 extension study.
Results for glioma incidence were assessed using with time-to-event approaches. The total number of events and the annualized percentage are reported (Supplementary table 2) .
Univariate and multivariate Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for the associations among glioma risk and HT use and other demographic, reproductive and hormonal factors. Stratification was based on five-year demographic age groups and WHI DM trial randomization (intervention, control, or nonparticipant) and CaD trial randomization (active, placebo, or non-participant). Results from univariate models of risks and from a multivariate model of all risk factors are presented. Models with a subset of risk factors (e.g., age, socioeconomic status, and hormone exposure) were also considered during the evaluation of the full multivariate model. Glioma rates over time were assessed by Kaplan-Meier analysis with logrank test from time of enrollment in the WHI trial to time of cancer diagnosis. All significance levels are two-sided, and a p-value of 0.05 was considered statistically significant. All statistical tests were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
Results
Demographic characteristics of the study subjects are shown by HT status (Table 1) .
Hormonal characteristics including type and duration of hormone use, as well as reproductive characteristics such as age of menarche, age of first parity, number of pregnancies, months breastfeeding, oophorectomy status and years since menopause are shown in Table 2 . Tumor diagnoses, localization, morphology, and site characteristics are shown among different treatment groups (Table 3) . Overall, 167 cases of glioma, including 130 cases of GBM, were analyzed. Subsequent models were used to evaluate tumor incidence after adjusting for demographic, hormonal, and reproductive characteristics.
Univariate and multivariate Cox proportional hazards modeling were performed for HR of glioma incidence among demographic, hormonal and reproductive characteristics ( Kaplan-Meier survival plots for time-to-incidence of glioma from enrollment in the WHI trial among subjects in E-alone and E+P treatment groups was performed. For the E-alone group, no significant difference in incidence was observed between users and non-users (p=0.725) (Figure 2A ). However for the E+P group, a significant difference was seen where users showed increased time in glioma incidence compared to non-users (p=0.0035) ( Figure 2B ). KaplanMeier analysis of glioma or GBM case time-to-incidence in subjects randomized in CT HT arm did not demonstrate a significant difference of HT in comparison untreated placebo controls.
Discussion
Our epidemiological cohort study suggests that glioma risk is significantly reduced in postmenopausal women receiving estrogen and progesterone (E+P) therapy. This secondary analysis of the WHI trial data evaluating 167 cases of glioma (130 cases of GBM) demonstrated a 43% and 52% reduction in glioma risk in subjects in the E+P group by univariate and multivariate Cox proportional hazards analysis, respectively. Moreover, Kaplan-Meier survival analysis also showed a significant reduction in time-to-incidence with the E+P group. No reduction in glioma incidence by Cox proportional hazards or Kaplan-Meier survival analysis was shown for the E-alone group in our analysis and no differences in glioma incidence were also seen between the E-alone or E+P groups and their matched controls in the HT arm of the analysis.
A number of case-control and cohort studies have suggested that estrogens play an important role in GBM incidence but with inconsistent results (Felini et al. 2009; Hatch et al. 2005; Huang et al. 2004; Kabat et al. 2011; Lambe et al. 1997; Michaud et al. 2010; Silvera et al. 2006; Wigertz et al. 2008 ). Several case-control studies showed statistically significant odds Our analysis suggests a reduced risk of glioma in subjects treated with E+P but has several limitations. The primary strengths of this study are the large sample size, prospective detection of adjudicated glioma cases, and detailed determination of HT exposure as well as type.
Interestingly in our study, the E-alone model did not show a significant reduction in glioma risk.
This result may have been due to the heterogeneity of reproductive factors relating to hormone exposure in comparison to previous studies. On the other hand, our study suggests that progesterone may play an important role in gliomagenesis, which may not have been account in previous studies. Progesterone has been shown to be neuroprotective independently from estrogen and to affect glioma proliferation in vitro (Cabrera-Muñoz et al. 2011; Coughlan et al. 2009; Cowppli-Bony et al. 2011; Inoue et al. 2002) . While reproductive characteristics were evaluated as potential confounders in our models, details regarding hormone type and duration of exposure prior to trial recruitment were obtained at the onset of enrollment. Therefore, recall bias may have been a significant possibility. In addition, the inclusion of subjects into the E-alone and E+P groups not solely from the randomized CT HT may introduce a selection bias. However the duration and type of hormonal exposure along with other reproductive characteristics were adjusted for in the multivariate models and the inclusion of all WHI participants allowed us to achieve sufficient statistical power to test these associations. Furthermore, the effect of estrogen and progesterone on GBM cases may have not been significant because of limited sample size.
In addition, limitations of the study include the mean age of participants in the WHI trial being 65 years of age where aggregated hormone exposure may have been after clinically detectable glioma formation.
Various molecular studies also support the role of E+P in the inhibition of glioma.
Several estrogen receptors (ER) have been described including, ERα, ERβ, and a G-protein functional isoforms (with PR-A overexpression shown to reduce in vitro astrocytoma growth (Cabrera-Muñoz et al. 2009; Felini et al. 2009; Hatch et al. 2005; Huang et al. 2004; Inoue et al. 2002; Kabat et al. 2011; Lambe et al. 1997; Michaud et al. 2010; Silvera et al. 2006; Wigertz et al. 2008) . Progesterone treatment alone did not result in improved animal survival in one study (Plunkett et al. 1999) . However, the understanding of impact of PRs in gliomas is much more limited than the effect of ERs. Furthermore, the effect of combined E+P on glioma or GBM has not been evaluated with in vitro, animal models or clinical trials to date. The presence of these hormone receptors and how they interact with various glioma signaling pathways may indicate their importance in gliomagenesis.
The results of this study suggest that E+P therapy reduces glioma risk but the reproductive variables did not show a significant effect on risk in our study. Studies in parous women have shown lower levels of androgens, prolactin, and free estradiol and higher levels of sex hormonebinding globulin, which may support reduced risk of estrogen-sensitive breast carcinomas in parous women (Chubak et al. 2004 ). Furthermore, breastfeeding suppresses ovulation and net estrogen exposure while inducing prolactin and oxytocin secretion. Parity, breastfeeding, and oophorectomy would have been expected to increase glioma risk while higher body-mass index and oral contraceptive would have been expected to decrease glioma risk by altering net estrogen exposure. Interestingly, prolactin has been shown to promote glioma cell proliferation (Ducret et al. 2002) while oxytocin can inhibit cell proliferation (Cassoni et al. 1998) . It may be possible that estrogen generates distinct regulation in normal and neoplastic tissue suggesting that selective modulation, altered signaling pathways and parallel hormonal signaling may govern the protective effects of estrogen in some cancers (Kabat et al. 2010) . Further molecular studies are necessary to identify key hormonal signaling networks involved in gliomagenesis.
A better understanding of estrogen and progesterone may aid in the design of rational, targeted therapies in glioma. The use of selective estrogen receptor modulators (SERMs), which are selective receptor agonists and/or antagonists depending on receptor and site, may play a role in the treatment of this disease. Tibolone, an ER antagonist, has been shown to reduce proliferation of human and rat GBM cells (Altinoz et al. 2009 ). In another study, genistein, an isoflavone that binds to ERβ, showed reduced DNA synthesis in glioma cells (Yakisich et al. 2009 ). In several studies, the SERM tamoxifen showed inhibition of glioma cell proliferation and increased apoptosis (Hui et al. 2004; Kim et al. 2005; Liu et al. 2001; Pollack et al. 2010; Zhang et al. 2000) , and in several other studies, RU486 (mifepristone), a progestin receptor antagonist, has also been shown to suppress GBM proliferation and tumor volume in a xenografted GBM cell line (Pinski et al. 1993; Ramaswamy et al. 2012) . Currently clinical trials of SERM and other hormonal agents in glioma have been limited (Patel et al. 2012; Sankar et al. 2008 ).
Conclusion
In conclusion, the results of this study suggest a reduced glioma risk for subjects in association with E+P therapy. Furthermore, these results were constant after controlling for demographic, reproductive and hormonal characteristics. Limitations in patient selection and hormone exposure limit the findings and support the need for well-designed, prospective studies for evaluating the impact of E+P treatment on glioma incidence.
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Kaplan-Meier survival analysis and logrank test of glioma survival for Caucasian participants in the E-alone or E+P groups. A) No statistically significant difference in incidence was seen for E-alone users compared with non-users. B) A statistically significant decreased incidence was seen for E+P users compared with non-users (p=0.0035).
Table 1(on next page)
Demographic characteristics of HT users and non-users Hormonal and reproductive characteristics of HT users and non-users Glioma -malignant 1 (3.7%) 2 (4.7%) 3 (4.2%) 0 (0.0%) Gliosarcoma 0 (0.0%) 0 (0.0%) 2 (2.8%) 0 (0.0%) Mixed glioma 0 (0.0%) 0 (0.0%) 1 (1.4%) 2 (7.7%) Oligodendroglioma, anaplastic 0 (0.0%) 1 (2.3%) 2 (2.8%) 0 (0.0%) Oligodendroglioma NOS 0 (0.0%) 0 (0.0%) 3 (4.2%) 0 (0.0%)
Site description
Brain NOS 3 (11.1%) 3 (7.0%) 4 (5.6%) 4 (15.4%) Brain stem 0 (0.0%) 2 (4.7%) 0 (0.0%) 0 (0.0%) Cerebrum 1 (3.7%) 3 (7.0%) 5 (7.0%) Cox proportional regression modeling of hazard risk in subjects receiving HT 
